Completed NA INTERVENTIONAL 1-arm NCT02807129

Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer (AgElOn)

Sponsor: CHU de Reims

Conditions Cancer

Interventions blood withdrawn urine collection

Updated 10 times since 2017 Last updated: Jan 19, 2026 Started: Jan 29, 2014 Primary completion: Jan 16, 2023 Completion: Jan 16, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02807129, this NA trial focuses on Cancer and remains completed. Sponsored by CHU de Reims, it has been updated 10 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed NA
Feb 2025 — Feb 2026 [monthly]

Completed NA

Status: Unknown → Completed
Sep 2024 — Feb 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status

▶ Show 5 earlier versions

Jan 2021 — Feb 2024 [monthly]

Recruiting NA
Nov 2019 — Jan 2021 [monthly]

Recruiting NA
Jun 2018 — Nov 2019 [monthly]

Recruiting NA
Jun 2017 — Jun 2018 [monthly]

Recruiting NA
Jan 2017 — Jun 2017 [monthly]

Recruiting NA

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHU de Reims

Data source: CHU de Reims

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reims, France